跳至主要内容
临床试验/ISRCTN10396126
ISRCTN10396126已完成不适用

Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy

Sun Yat-sen University0 个研究点目标入组 45 人开始时间: 2017年6月7日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Treatment-naive PCV characterized by the presence of polyps with or without BVN in posterior pole on ICGA, with subretinal/intraretinal fluids observed on optical coherence tomography (OCT) or leakage on fluorescein angiography (FA)
  • 2. Received three continuous monthly intravitreal injections of 0.5 mg conbercept followed by as-needed injections
  • 3. Pro re nata (PRN). Reinjection was considered if any intraretinal or subretinal fluid was observed after the third injection.
  • 4. Underwent intravitreal conbercept injections as the primary treatment for PCV and completed at least six months of monthly follow-up exams after the first treatment
  • 5. Aged 50 and older

排除标准

  • 1. Angioid streaks, multifocal choroiditis, punctate inner choroidopathy, pathologic myopia, retinal angiomatous proliferation or other diseases that can cause choroid neovascularization
  • 2. The presence of any other ocular diseases that might affect visual acuity
  • 3. Received any other treatment, including thermal laser photocoagulation, submacular surgery, intravitreal any other anti-VEGF drugs, and photodynamic therapy (PDT)

研究者

发起方
Sun Yat-sen University

相似试验